<DOC>
	<DOC>NCT01540487</DOC>
	<brief_summary>The aim of the trial is to assess the relative bioavailability of fixed dose combination tablets of linagliptin and metformin compared to the administration of two single tablets (linagliptin and metformin ) in Chinese subjects. The availability of a fixed dose combination tablet is expected to significantly enhance patients` compliance with antidiabetic treatment., in particular with concern to the frequent polypharmacy in diabetic patients.</brief_summary>
	<brief_title>Pharmacokinetics of Fixed Dose Combination (FDC) Tablets of Linagliptin /Metformin</brief_title>
	<detailed_description />
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Inclusion criteria: 1. Healthy male and female subjects Exclusion criteria: 1. Any relevant deviation from healthy conditions</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>